Gilead Sciences, INC 8-K filings

Gilead Sciences reported a substantial net loss for Q2 2026, primarily due to significant acquisition-related expenses, despite a 10% increase in total revenues driven by its base business, excluding Veklury.

Gilead Sciences, Inc. announced the pricing of a $3 billion senior notes offering across four tranches with maturities ranging from 2028 to 2034.

Gilead Sciences reported first quarter 2026 results with total revenues up 4% to $7.0 billion, driven by strong performance in its base business, particularly HIV products, and raised full-year revenue guidance.

Gilead Sciences held its 2026 annual meeting, re-electing nine directors and approving an amended equity incentive plan, while rejecting several stockholder proposals.

Gilead Sciences has finalized its acquisition of Arcellx, Inc., for approximately $7.8 billion, gaining full control of the investigational CAR T-cell therapy anito-cel for multiple myeloma.

Gilead Sciences announced a definitive agreement to acquire Arcellx for an implied equity value of $7.8 billion, gaining full control of the promising BCMA-directed CAR T-cell therapy anito-cel for multiple myeloma.

Gilead Sciences announced robust fourth quarter and full year 2025 financial results, driven by HIV and Liver Disease product growth, and provided optimistic 2026 guidance.

Gilead Sciences, Inc. announced that Deborah H. Telman will depart from her role as Executive Vice President, Corporate Affairs and General Counsel effective December 5, 2025.

Gilead Sciences reports a 3% increase in Q3 2025 total revenues to $7.8 billion, driven by robust HIV and Livdelzi sales, and an extended Biktarvy patent exclusivity.

Gilead Sciences has secured settlement agreements with generic manufacturers, ensuring Biktarvy's U.S. market exclusivity until April 1, 2036.

Gilead Sciences, Inc. announced the appointment of Erin Burkhart as Senior Vice President, Controllership and principal accounting officer, effective September 22, 2025.

Gilead Sciences reports strong second quarter 2025 financial results, driven by HIV and oncology sales, leading to an increase in full-year revenue and earnings guidance.

Gilead Sciences, Inc. has amended its bylaws to update corporate governance provisions, including enhanced shareholder proposal and director nomination procedures, and to align with recent Delaware law changes.

Gilead Sciences held its annual meeting on May 7, 2025, where stockholders elected directors, ratified the selection of Ernst & Young LLP as the independent auditor, and voted on several proposals.

Gilead Sciences reports flat revenue for Q1 2025, but sees growth in HIV and Liver Disease sales offsetting declines in Veklury and Oncology.

Sandra Patterson, Gilead Sciences' Senior Vice President, Corporate Controller, and Chief Accounting Officer, is leaving the company, and Diane E. Wilfong has been appointed as the interim replacement.

Gilead Sciences announces positive financial results for Q4 and full year 2024, highlighting growth in HIV, Oncology, and Liver Disease product sales.

Gilead Sciences has announced the appointment of Dietmar Berger as its new Chief Medical Officer, succeeding Merdad Parsey, effective January 2, 2025.

Gilead Sciences has successfully priced and issued $3.5 billion in senior notes across four tranches to support general corporate purposes, including potential debt repayment.

Gilead Sciences announced robust third-quarter 2024 financial results, driven by strong product sales, leading to an increase in full-year revenue, operating income, and earnings per share guidance.

Gilead Sciences announced a 5% increase in total revenue to $7.0 billion for the second quarter of 2024, driven by strong performance in HIV, Liver Disease, and Oncology.

Gilead Sciences announced that its Chief Medical Officer, Merdad Parsey, will be leaving the company in early 2025, initiating a search for his successor.

Gilead Sciences' stockholders approved amendments to the company's charter and elected nine directors at the 2024 annual meeting.

Gilead Sciences' first quarter results show revenue growth driven by HIV, Oncology and Liver Disease, but are impacted by significant acquisition-related charges.

Gilead Sciences has finalized its acquisition of CymaBay Therapeutics for approximately $4.3 billion, adding a potential best-in-disease therapy for primary biliary cholangitis to its portfolio.

Gilead Sciences' director, Kevin E. Lofton, has announced his retirement from the Board, effective at the conclusion of the next annual meeting of stockholders on May 8, 2024.

Gilead Sciences will acquire CymaBay Therapeutics for $4.3 billion, adding the promising drug seladelpar to its liver disease treatment pipeline.

Gilead Sciences' fourth quarter revenue declined by 4% year-over-year, while full year product sales excluding Veklury increased by 7%, driven by strong oncology growth.

Gilead Sciences has expanded its Board of Directors by appointing Ted Love, M.D., effective February 1, 2024.